The aim of using a contrast agent in Magnetic Resonance Imaging is to accelerate the relaxation of water protons in the surrounding tissue. This objective can be achieved by paramagnetic substances. In 1948, Bloch et al. reported the use of the paramagnetic ferric nitrate salt to enhance the relaxation rates of water protons [1]. Some 30 years later, Lauterbur et al. applied a Mn(II) salt to distinguish between different tissues based on the differential relaxation times and thus produced the first MR image [2]. Nowadays, Gd(III) complexes are far the most widely used MRI contrast agents in the clinical practice. The choice of Gd(III) is explained by its seven unpaired electrons which makes it the most paramagnetic stable metal ion. Beside this, Gd(III) has another significant feature: owing to the symmetric S-state, its electronic relaxation is relatively slow which is relevant to its efficiency as an MRI contrast agent.As most of the current contrast agent applications in MRI concerns Gd(III) complexes, this chapter will focus on the discussion of relaxation theory and the experimental results on Gd(III)-based agents. Several reviews have been published on this topic [3][4][5][6][7]. In addition to Gd(III) compounds, a Mn(II) chelate, Mn(II)DPDP, is the only metal complex which has been approved as an MRI contrast agent (DPDP = N,N -dipyridoxylethylenediamine-N,N -diacetate 5,5 -bis(phosphate)) [8]. Mn(II)DPDP is a weak chelate that dissociates in vivo to give free manganese which is taken up by hepatocytes [9]. The presence of the ligand is necessary because it facilitates a slower release of manganese than would have been the case had manganese been administered as a simple salt, such as manganese chloride.